Drivers and barriers: Innovation in healthcare Alberto Spinazzi, Bracco Chief Medical and Regulatory Officer, answers some of these questions by illustrating future trends and the importance of prevention for human health.

Concluso il progetto Cathena: la nanomedicina personalizzata Concluso il progetto Cathena: la nanomedicina personalizzata

Fabbrica del Vapore: il primo Festival “In and Aut" Dal 13 al 15 maggio Milano ha ospitato alla Fabbrica del Vapore il primo Festival "In & Aut" per promuovere l’inclusione sociale delle persone affette da disturbi dello spettro autistico.

Diana Bracco al Convegno SIRM: “La scienza ha bisogno delle donne” Diana Bracco al Convegno SIRM: “La scienza ha bisogno delle donne”

Diana Bracco “A Torviscosa Spin continua a investire in cultura” Negli anni passati, per sviluppare il patrimonio artistico e culturale di questi territori, Fondazione Bracco e Spin hanno messo in campo diverse iniziative.

Anti-corruption The Global Anti-Corruption Program provides guidance on how to conduct business in a fair, ethical, and legal manner and summarizes the laws and principles to which everyone working for the Bracco Group must adhere.

Politique de la qualité Bracco is committed to provide safe, reliable, effective products and services for the Patients and Customers through Quality excellence. The Quality organization has the appropriate level of independence and authority to act using the highest quality standards and promoting the quality culture company-wide.

Bracco’s “The Beauty of Imaging” The multimedia installation explaining the importance of diagnostic imaging is now on display at STEP, to relate the future of radiology and precision medicine

Bracco joins the UN Global Compact The UN Global Compact is a call to companies everywhere to align their operations and strategies with ten universally accepted principles in the areas of human rights, labour, environment and anti-corruption.

Efficacy and Safety of Gadopiclenol The results of the multicenter, multinational PICTURE clinical trial demonstrate that 0.05 mmol/kg gadopiclenol provides similar morphologic information about CNS lesions and greater contrast enhancement compared with 0.1 mmol/kg gadobutrol.